YD Bio Limited (YDES)
NASDAQ:YDES
Want to see YDES full AI Analyst Report?
YDES Stock Chart & Stats
$3.39
$0.12(3.67%)
―
--
Day’s Range― - ―
52-Week Range$2.88 - $25.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)91.42K
Market Cap
$231.48M
Enterprise Value$222.08M
Total Cash (Recent Filing)$6.31K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.36
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding70,789,260
10 Day Avg. Volume96,756
30 Day Avg. Volume91,419
Financial Highlights & Ratios
PEG Ratio1.25
Price to Book (P/B)-284.80
Price to Sales (P/S)1362.74
P/FCF Ratio-101.20
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-74.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Reported DebtLow reported debt materially reduces near-term interest and refinancing obligations, giving management flexibility to prioritize R&D and regulatory work. For a clinical-stage biotech, limited leverage preserves optionality for equity-funded development and de-risks short-term solvency.
Recent Capital Infusion (SPAC + $13.2M PIPE)The SPAC combination and $13.2M PIPE provide a structural increase in available capital, reducing immediate liquidity pressure and enabling multi-quarter R&D, regulatory filings, and U.S. expansion. This financing underpins execution of clinical/registration milestones that can create lasting value.
Advancing Regulatory Programs And Platform LaunchProgress toward INDs/Q-submissions and a March 2026 telehealth platform launch represent structural product and commercialization building blocks. These regulatory steps and platform integration (including planned DNA methylation AI merger) can create durable competitive positions across multiple healthcare verticals if executed.
Bears Say
Accelerating Cash BurnPersistent negative operating and free cash flows with accelerating burn create ongoing funding needs and raise refinancing risk. Over a 2-6 month horizon this forces management to pursue dilutive financings or partnerships, constraining strategic optionality and increasing execution risk.
Negative Equity / Balance-sheet StrainA move to negative equity signals accumulated losses that impair financial flexibility: lenders and partners face higher credit risk and future financing may be more dilutive or restrictive. This structural weakness elevates the probability of recapitalization or distressed funding needs.
Small Revenue Base & Margin DeteriorationRevenue remains tiny and gross profit turned negative as the company pivoted to lower-margin drugs while increasing operating spend. Limited top-line scale and deteriorating margins weaken operating leverage, extending the time and capital required to reach sustainable profitability.
YD Bio Limited News
YDES FAQ
What was YD Bio Limited’s price range in the past 12 months?
YD Bio Limited lowest stock price was $2.88 and its highest was $25.00 in the past 12 months.
What is YD Bio Limited’s market cap?
YD Bio Limited’s market cap is $231.48M.
When is YD Bio Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were YD Bio Limited’s earnings last quarter?
Currently, no data Available
Is YD Bio Limited overvalued?
According to Wall Street analysts YD Bio Limited’s price is currently Undervalued.
Does YD Bio Limited pay dividends?
YD Bio Limited does not currently pay dividends.
What is YD Bio Limited’s EPS estimate?
YD Bio Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does YD Bio Limited have?
YD Bio Limited has 70,789,260 shares outstanding.
What happened to YD Bio Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of YD Bio Limited?
Currently, no hedge funds are holding shares in YDES
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
YD Bio Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
YD Bio Limited
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
Scinai Immunotherapeutics
―
Aditxt
―
SciSparc Ltd.
―
CDT Equity
―
Virax Biolabs Group Ltd. Class A
―
Ownership Overview
―
Insiders
0.06% Mutual Funds
0.04% Other Institutional Investors
99.87% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---